Bayer to buy Perfuse Therapeutics for $300M upfront

May 6, 2026 06:56 AM EDTUpdated 01:00 PM Deals Bay­er dips toes back in­to phar­ma M&A to buy Per­fuse Ther­a­peu­tics Ayisha Sharma News Reporter Bay­er is com­mit­ting $300 mil­lion up­front to buy oph­thal­mol­o­gy biotech Per­fuse Ther­a­peu­tics and its mid-stage pro­gram tar­get­ing the lead­ing caus­es of blind­ness. The Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER